Evidence map›Paper›PMID 37528387›Full record

ArticleBMC medical education2023

Pharmacovigilance practice among pediatric neurologists from Poland and Germany.

Dorota Kopciuch, Krzysztof Kus, Izabela Niśkiewicz, Jędrzej Fliciński, Tomasz Zaprutko, Piotr Ratajczak, Elżbieta Nowakowska, Karolina Hoffmann, Agnieszka Koligat-Seitz, Wiesław Bryl and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC medical education, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Dorota KopciuchDepartment of Pharmacoeconomics and Social Pharmacy, Poznan University of Medical Sciences, Rokietnicka 7 St, 60-806, Poznań, Poland. dkoligat@ump.edu.pl.
Krzysztof KusDepartment of Pharmacoeconomics and Social Pharmacy, Poznan University of Medical Sciences, Rokietnicka 7 St, 60-806, Poznań, Poland.
Izabela NiśkiewiczDepartment of Neurology, Martin-Luther-University Hospital Halle- Wittenberg, Halle, Germany.
Jędrzej FlicińskiDepartment of Developmental Neurology, Poznan University of Medical Sciences, Poznan, Poland.
Tomasz ZaprutkoDepartment of Pharmacoeconomics and Social Pharmacy, Poznan University of Medical Sciences, Rokietnicka 7 St, 60-806, Poznań, Poland.
Piotr RatajczakDepartment of Pharmacoeconomics and Social Pharmacy, Poznan University of Medical Sciences, Rokietnicka 7 St, 60-806, Poznań, Poland.
Elżbieta NowakowskaDepartment of Pharmacology and Toxicology Institute of Health Sciences, Collegium Medicum, University of Zielona Gora, Góra, Poland.
Karolina HoffmannDepartment of Internal Diseases, Metabolic Disorders and Arterial Hypertension, Poznan University of Medical Sciences, Poznan, Poland.
Agnieszka Koligat-SeitzDepartment of Otolaryngology, Greater Poland Pediatric Center, Poznan, Poland.
Wiesław BrylDepartment of Internal Diseases, Metabolic Disorders and Arterial Hypertension, Poznan University of Medical Sciences, Poznan, Poland.
Anna PaczkowskaDepartment of Pharmacoeconomics and Social Pharmacy, Poznan University of Medical Sciences, Rokietnicka 7 St, 60-806, Poznań, Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo compare the pediatric neurologists' knowledge, practice, and barriers to the pharmacovigilance (PV) process in Poland and Germany.

methodsThe research tool was an online anonymous questionnaire on Google Forms e-mailed to pediatric neurologists from Poland and Germany.

resultsThe questionnaires were handed out to 830 pediatric neurologists and 371 expressed their consent to participate in the study. Most of the neurologists were familiar with the definition of PV and adverse drug reactions (ADRs). Only 34.10% of pediatric neurologists from Poland, and 38.88% from Germany believe that many ADRs are preventable and almost most of them believe it is necessary to report ADRs from children with epilepsy. Unfortunately, in opposite to this knowledge, only 37.79% of respondents from Poland and 40.32% from Germany felt co-responsible for reporting ADRs. The main reason for the neurologists not to report ADRs was a conviction that reporting ADRs would be an additional burden generating extra work.

conclusionThere is no big difference between the practice of PV by pediatric neurologists in Poland and Germany. System-regulated PV stabilization in the country translates into the practice of maintaining PV. Monitoring the safety of pharmacotherapy and knowledge of risks associated with ADRs should be included in the curricula of academic neurologics courses.

Indexed as

Drug-Related Side Effects and Adverse ReactionsNeurologistsAdverse Drug Reaction Reporting SystemsChildGermanyHealth Knowledge, Attitudes, PracticeHumansPharmacovigilancePolandAdverse drug reactionsChildren with epilepsyDrug safetyEpilepsyGermanyNeurologists’ knowledgePharmacovigilancePoland

Identifiers

PMID37528387
PMCPMC10394771

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.